Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Edwards Lifesciences Corp (EW) executive Andrew M. Dahl, SVP, Corporate Controller, reported a sale of 544 shares of Common Stock on 2026-08-31 at $91.055 per share in an open-market or private transaction. After this sale, he directly holds 14,868.41 shares of Edwards Lifesciences common stock. The filing states it reflects changes in beneficial ownership and notes quarterly acquisition of shares under the company’s Employee Stock Purchase Plan. The Rule 10b5-1 trading-plan box is not checked.
Edwards Lifesciences Corp (EW) is the issuer for a notice of proposed sale of securities filed for the account of officer Andrew M. Dahl under Rule 144. The filing covers up to 544 shares of common stock, held at Charles Schwab & Co., Inc., relating to a restricted stock lapse scheduled on 05/08/2026 and designated as Equity Compensation. The common stock is listed on the NYSE. The form indicates an outstanding share count of 576,400,000 common shares, which is a baseline figure for the issuer.
Edwards Lifesciences Corp (EW) reported an insider sale by Annette Bruls, CVP, EMEACLA. On 2026-08-28, she sold 2,644 shares of Common Stock at $89.98 per share in an open market or private transaction. Following this sale, she directly holds 17,984 shares of Edwards Lifesciences common stock.
Edwards Lifesciences Corp (EW) is the issuer for which officer Annette Bruls filed a notice under Rule 144 to permit the sale of common stock. The filing covers up to 2,644 shares of common stock to be sold through Charles Schwab & Co., Inc. on the NYSE, with an aggregate market value of $237,907.00 and total shares outstanding of 576,400,000. The securities to be sold include shares acquired via restricted stock lapses from equity compensation awards.
Edwards Lifesciences Corporation (EW) reported that its Corporate Vice President, Strategy and Corporate Development, Donald E. Bobo, Jr., has notified the company of his decision to retire by mid-year 2027. The board will begin a selection process promptly to identify a successor, with a transition of duties expected during 2027.
The company also states that Mr. Bobo is expected to remain with Edwards as a consultant through the end of 2027, providing continuity during and after the leadership transition.
Edwards Lifesciences Corp (EW) executive Daveen Chopra, CVP, TMTT, Surgical & IHFM, exercised 31,800 Employee Stock Options for Common Stock at an exercise price of $72.68 per share and simultaneously sold 31,800 shares of Common Stock on 2026-08-26 in open-market transactions. The sales comprised 1,154 shares at a weighted average price of $91.7614 (individual trades ranged from $91.660 to $91.975) and 30,646 shares at a weighted average price of $90.9922 (trades ranged from $90.645 to $91.640). The option, originally exercisable since 2021-05-07 and expiring on 2027-05-06, now shows 0 options remaining in this grant.
Edwards Lifesciences Corp (EW) reported an insider sale by Wayne Markowitz, CVP, JAPAC. On 2026-08-26, he sold 1,240 shares of Common Stock in a sale classified as an open market or private transaction at a reported price of $91.465 per share. After this transaction, he directly holds 20,293.5581 shares of Edwards Lifesciences common stock. The filing notes that it reflects only changes in beneficial ownership and does not list all securities beneficially owned.
Edwards Lifesciences Corp (EW) is the issuer for a Rule 144 notice filed for officer Wayne Markowitz. The filing covers a proposed sale of 1,240 shares of Edwards Lifesciences common stock, with an aggregate market value of $113,417.00 and 576,400,000 shares outstanding as of August 26, 2026. The shares to be sold arise from equity compensation via restricted stock lapses of 537, 111, and 592 shares on specified future dates. Over the prior three months, Markowitz reported sales of 9,628 shares for $818,958.00 and 147 shares for $12,588.00.
Edwards Lifesciences Corp (EW) received a notice under Rule 144 that officer Daveen Chopra may sell up to 31,800 shares of Edwards Lifesciences common stock through broker Charles Schwab & Co., Inc. The planned sale is associated with an Employee Stock Option Exercise and is listed to occur on 08/26/2026 on the NYSE.
Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, reported an option exercise and related stock sale. He exercised 619 Employee Stock Options at an exercise price of $72.68 per share, receiving 619 shares of Common Stock, and then sold 619 shares of Common Stock at $92.03 per share. Following the option exercise, he reported holding 4,333 options for Common Stock. The equity trades referencing the plan were effected pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2026.